1. Prognostic Values of Transforming Growth Factor-Beta Subtypes in Ovarian Cancer.
- Author
-
Zhou, Junhan, Jiang, Wenxiao, Huang, Wenbin, Ye, Miaomiao, and Zhu, Xueqiong
- Subjects
- *
CANCER chemotherapy , *CANCER patients , *COMBINATION drug therapy , *DATABASES , *GENE expression , *IMMUNOHISTOCHEMISTRY , *MESSENGER RNA , *GENETIC mutation , *ONCOGENES , *OVARIAN tumors , *PACLITAXEL , *PLATINUM , *SURVIVAL , *TRANSFORMING growth factors-beta , *TUMOR markers , *TUMOR classification , *KAPLAN-Meier estimator - Abstract
Purpose. To explore the potential role of the transforming growth factor-beta (TGF-β) subtypes in the prognosis of ovarian cancer patients. Materials and Methods. The prognostic roles of individual TGF-β subtypes in women with ovarian cancer were retrieved from the Kaplan-Meier plotter (KM plotter) database. In addition, the Oncomine database and immunohistochemistry were used to observe the mRNA and protein expression of TGF-β subtypes between human ovarian carcinoma and normal ovarian samples, respectively. Results. TGF-β1 and TGF-β4 were totally uncorrelated with survival outcomes in women with ovarian cancer. Increased TGF-β2 and TGF-β3 mRNA expression was markedly related to unfavorable prognosis, especially in women with serous, poorly differentiated, and late-stage ovarian carcinoma. High expression levels of TGF-β2 were related to worse progression-free survival (PFS) while TGF-β3 was linked to unfavorable overall survival (OS) and PFS in women with TP53-mutated ovarian cancer. TGF-β2 was associated with poor OS and PFS from treatment with chemotherapy with platins, Taxol, or a platin+Taxol. However, overexpression of TGF-β3 was associated with poor OS from the use of platins and poor PFS of Taxol or a platin+Taxol in women with ovarian carcinoma. Furthermore, the expression of TGF-β2 mRNA and protein was higher but only TGF-β3 mRNA expression was higher in cancerous tissues than in normal ovarian samples. Conclusion. Higher expression of TGF-β2 functioned as a significant predictor of poor prognosis in women with ovarian cancer, especially those with TP53 mutations or who were undergoing chemotherapy with platins, Taxol, or a platin+Taxol. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF